Ace Blend Raises $9.91 Mn Series A2 Led By 3one4 Capital

Ace Blend, an Indian nutrition startup, has raised $9.91 million in a Series A2 round led by 3one4 Capital, with existing investor Fireside Ventures increasing its stake. The money will go into research-led product development and new nutrition formats.

The company says it grew 300% in FY26 and that more than 46% of its customers returned to buy again. It did not disclose its revenue base, so the growth figure should be read as a company claim until the numbers are filed.

What Ace Blend Sells

Ace Blend develops nutritional products using clinical evidence to guide ingredient selection, dosage and delivery. Its portfolio spans heart health, immunity, sleep, recovery and brain health.

Read More: Venttup Raises $3 Mn From Rainmatter And Unicorn India Ventures

Fundingdubdub Raises $1.3 Mn To Turn The Scroll Into A QuizEntrepreneur16-Year-Old Samara Roy Builds Beauty Brand SAMMMM To 17x Sales Growth

The company’s argument is about form rather than marketing. A nutrient behaves differently depending on the molecule used, the dose delivered and the way the body absorbs it. Ace Blend builds products around those three choices.

Read More: Subransu Mohanty Invests ₹2 Crore in Saesha Industrial Enterprises, Acquires 27% Stake

That is a slower way to launch a consumer brand than picking a trending ingredient. It is also the only way to sell to doctors, which is the channel the company has chosen.

The Doctor Channel

Ace Blend says its products are developed by an in-house clinical team and recommended by a network of more than 400 doctors. That is a distribution strategy as much as a quality claim.

Supplement brands in India mostly buy attention on marketplaces. A doctor-led brand pays for credibility instead. Credibility compounds when a patient is told to continue a course.

The company also says clinical validation and automated testing are done independently by accredited laboratories in Europe. It has not named those labs or published the studies, so the claim cannot be checked from the announcement alone.

The Supply Chain Bet

Ace Blend controls sourcing, formulation and manufacturing rather than outsourcing all three. It also works with global ingredient suppliers DSM and TCI. The company says those partnerships give it exclusive rights in India to certain technologies.

Exclusivity on an ingredient is a real moat when it holds, because a competitor can copy the packaging and the price but not the input.

The risk is concentration. A brand that depends on two suppliers for its differentiation has to manage those relationships as carefully as it manages customers.

Who Is Behind It

Ace Blend was founded by Shivam Hingorani and began selling products in 2018. Saif Mehkri joined as co-founder in 2022 with nearly three decades in the nutrition industry.

Fireside Ventures previously led a $3.3 million pre-Series A round. Its decision to invest again signals that the early thesis has held. 3one4 Capital coming in as lead is the first institutional validation at this scale.

Ace Blend is also competing in a category where the last decade produced many brands and few durable ones. Most Indian nutrition startups stalled after the first product line, once customer acquisition costs outran repeat purchases.

What to Watch

Three numbers will decide the next round. The first is repeat rate measured over a year, not a quarter. Supplements are bought in cycles, and 46% looks very different across 12 months.

The second is contribution margin after marketing. If 300% growth was bought with discounts, the next cheque pays for the same growth again.

The third is the doctor network’s productivity. Four hundred recommendations are worth more than four hundred names only if those doctors keep prescribing after the launch push ends.